Randomized, open-label study of the BRIA-IMT regimen and checkpoint inhibitor vs physician’s choice in advanced metastatic breast cancer (BRIA-ABC)
September 10, 2026
A Phase 1b/2 Open-Label Study of APVO436 in Combination with Venetoclax and Azacitidine in Newly Diagnosed Acute Myeloid Leukemia (AML)